{"entity":{"type":"insider","cik":"0001748177","url":"/insider/0001748177","json_url":"/insider/0001748177.json","name":"Valamehr Bahram","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":55,"n_filings":21,"first":"2019-10-16","last":"2026-08-05","span_basis":"filed_date"},"name_variants":[{"name":"Valamehr Bahram","source":"filing","n_filings":21,"first_seen":"2019-10-16","last_seen":"2026-08-05"}],"transactions":[{"id":6063487,"accession":"0001193125-26-335007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-335007","line_url":"/filing/0001193125-26-335007#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":43947.0,"shares_display":"43,947","price_per_share":2.4598,"price_display":"2.46","price_state":"stated","total_value":108100.8306,"total_display":"108,100.83","total_whole":"108,101","shares_owned_after":591815.0,"shares_owned_after_display":"591,815","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-04","filed_date":"2026-08-05","scope":"insider"},{"id":6134997,"accession":"0001193125-26-234380","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-234380","line_url":"/filing/0001193125-26-234380#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28946.0,"shares_display":"28,946","price_per_share":1.8822,"price_display":"1.88","price_state":"stated","total_value":54482.1612,"total_display":"54,482.16","total_whole":"54,482","shares_owned_after":635762.0,"shares_owned_after_display":"635,762","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-20","filed_date":"2026-05-21","scope":"insider"},{"id":5883677,"accession":"0001193125-26-010352","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-010352","line_url":"/filing/0001193125-26-010352#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5190.0,"shares_display":"5,190","price_per_share":1.0708,"price_display":"1.07","price_state":"stated","total_value":5557.452,"total_display":"5,557.45","total_whole":"5,557","shares_owned_after":329708.0,"shares_owned_after_display":"329,708","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-09","filed_date":"2026-01-12","scope":"insider"},{"id":4048946,"accession":"0000950170-25-102979","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-102979","line_url":"/filing/0000950170-25-102979#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14466.0,"shares_display":"14,466","price_per_share":1.0643,"price_display":"1.06","price_state":"stated","total_value":15396.1638,"total_display":"15,396.16","total_whole":"15,396","shares_owned_after":334898.0,"shares_owned_after_display":"334,898","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-04","filed_date":"2025-08-05","scope":"insider"},{"id":4047280,"accession":"0000950170-25-004814","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-004814","line_url":"/filing/0000950170-25-004814#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8705.0,"shares_display":"8,705","price_per_share":1.54,"price_display":"1.54","price_state":"stated","total_value":13405.7,"total_display":"13,405.70","total_whole":"13,406","shares_owned_after":349364.0,"shares_owned_after_display":"349,364","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-10","filed_date":"2025-01-13","scope":"insider"},{"id":2585979,"accession":"0000950170-24-003650","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-003650","line_url":"/filing/0000950170-24-003650#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11271.0,"shares_display":"11,271","price_per_share":4.38,"price_display":"4.38","price_state":"stated","total_value":49366.98,"total_display":"49,366.98","total_whole":"49,367","shares_owned_after":158069.0,"shares_owned_after_display":"158,069","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-09","filed_date":"2024-01-10","scope":"insider"},{"id":8069763,"accession":"0001209191-23-002978","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002978","line_url":"/filing/0001209191-23-002978#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10917.0,"shares_display":"10,917","price_per_share":5.24,"price_display":"5.24","price_state":"stated","total_value":57205.08,"total_display":"57,205.08","total_whole":"57,205","shares_owned_after":168917.0,"shares_owned_after_display":"168,917","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-11","scope":"insider"},{"id":6251938,"accession":"0001209191-22-041670","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-041670","line_url":"/filing/0001209191-22-041670#line-2","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17158.0,"shares_display":"17,158","price_per_share":30.23,"price_display":"30.23","price_state":"stated","total_value":518686.34,"total_display":"518,686.34","total_whole":"518,686","shares_owned_after":179834.0,"shares_owned_after_display":"179,834","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-07","filed_date":"2022-07-08","scope":"insider"},{"id":6892678,"accession":"0001209191-22-041440","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-041440","line_url":"/filing/0001209191-22-041440#line-3","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7842.0,"shares_display":"7,842","price_per_share":30.07,"price_display":"30.07","price_state":"stated","total_value":235808.94,"total_display":"235,808.94","total_whole":"235,809","shares_owned_after":179834.0,"shares_owned_after_display":"179,834","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-06","filed_date":"2022-07-07","scope":"insider"},{"id":6204700,"accession":"0001209191-22-018820","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-018820","line_url":"/filing/0001209191-22-018820","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":31.069314,"price_display":"31.07","price_state":"stated","total_value":776732.85,"total_display":"776,732.85","total_whole":"776,733","shares_owned_after":188156.0,"shares_owned_after_display":"188,156","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-14","filed_date":"2022-03-15","scope":"insider","n_lines":5},{"id":6119895,"accession":"0001209191-22-003170","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-003170","line_url":"/filing/0001209191-22-003170","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4570.0,"shares_display":"4,570","price_per_share":48.50219693654267,"price_display":"48.50","price_state":"stated","total_value":221655.04,"total_display":"221,655.04","total_whole":"221,655","shares_owned_after":146950.0,"shares_owned_after_display":"146,950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider","n_lines":2},{"id":6692915,"accession":"0001209191-22-003047","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-003047","line_url":"/filing/0001209191-22-003047","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5596.0,"shares_display":"5,596","price_per_share":46.3826876340243,"price_display":"46.38","price_state":"stated","total_value":259557.52,"total_display":"259,557.52","total_whole":"259,558","shares_owned_after":151453.0,"shares_owned_after_display":"151,453","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-10","filed_date":"2022-01-12","scope":"insider","n_lines":2},{"id":5016166,"accession":"0001209191-21-069415","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-069415","line_url":"/filing/0001209191-21-069415","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief R&D Officer)","role_mark":"O","role_mark_label":"Officer (Chief R&D Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief R&D Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":47.65622,"price_display":"47.66","price_state":"stated","total_value":1191405.5,"total_display":"1,191,405.50","total_whole":"1,191,406","shares_owned_after":158298.0,"shares_owned_after_display":"158,298","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-13","filed_date":"2021-12-14","scope":"insider","n_lines":5},{"id":4104162,"accession":"0001209191-21-055867","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-055867","line_url":"/filing/0001209191-21-055867","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":66.290296636,"price_display":"66.29","price_state":"stated","total_value":1657257.4159,"total_display":"1,657,257.42","total_whole":"1,657,257","shares_owned_after":104931.0,"shares_owned_after_display":"104,931","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-13","filed_date":"2021-09-14","scope":"insider","n_lines":3},{"id":4571190,"accession":"0001209191-21-040914","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-040914","line_url":"/filing/0001209191-21-040914","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":89.32180824,"price_display":"89.32","price_state":"stated","total_value":2233045.206,"total_display":"2,233,045.21","total_whole":"2,233,045","shares_owned_after":104360.0,"shares_owned_after_display":"104,360","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-14","filed_date":"2021-06-16","scope":"insider","n_lines":3},{"id":4305196,"accession":"0000899243-21-011920","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-21-011920","line_url":"/filing/0000899243-21-011920","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":92.350887208,"price_display":"92.35","price_state":"stated","total_value":2308772.1802,"total_display":"2,308,772.18","total_whole":"2,308,772","shares_owned_after":108367.0,"shares_owned_after_display":"108,367","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-15","filed_date":"2021-03-16","scope":"insider","n_lines":5},{"id":4715383,"accession":"0001209191-21-003340","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-003340","line_url":"/filing/0001209191-21-003340","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3254.0,"shares_display":"3,254","price_per_share":110.81370743700062,"price_display":"110.81","price_state":"stated","total_value":360587.804,"total_display":"360,587.80","total_whole":"360,588","shares_owned_after":79649.0,"shares_owned_after_display":"79,649","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-11","filed_date":"2021-01-12","scope":"insider","n_lines":3},{"id":4715370,"accession":"0001209191-21-003340","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-003340","line_url":"/filing/0001209191-21-003340","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6230.0,"shares_display":"6,230","price_per_share":117.10305473515248,"price_display":"117.10","price_state":"stated","total_value":729552.031,"total_display":"729,552.03","total_whole":"729,552","shares_owned_after":84455.0,"shares_owned_after_display":"84,455","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-08","filed_date":"2021-01-12","scope":"insider","n_lines":4},{"id":2517806,"accession":"0001209191-20-063449","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-20-063449","line_url":"/filing/0001209191-20-063449","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":97.779072308,"price_display":"97.78","price_state":"stated","total_value":2444476.8077,"total_display":"2,444,476.81","total_whole":"2,444,477","shares_owned_after":98633.0,"shares_owned_after_display":"98,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-14","filed_date":"2020-12-15","scope":"insider","n_lines":8},{"id":2737834,"accession":"0001209191-20-050683","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-20-050683","line_url":"/filing/0001209191-20-050683#line-6","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001748177","owner_name":"Valamehr Bahram","owner_display_name":"Valamehr Bahram","owner_url":"/insider/0001748177","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16784.0,"shares_display":"16,784","price_per_share":36.0256,"price_display":"36.03","price_state":"stated","total_value":604653.6704,"total_display":"604,653.67","total_whole":"604,654","shares_owned_after":94827.0,"shares_owned_after_display":"94,827","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-14","filed_date":"2020-09-16","scope":"insider"}],"collapsed":true,"next_cursor":"2020-09-14|2737834","ledger_fault":false,"count":{"value":55,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":55,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":55},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001434316","name":"FATE THERAPEUTICS INC","url":"/issuer/0001434316","role":"Director, Officer (President and CEO)","n_filings":21,"first_seen":"2019-10-16","last_seen":"2026-08-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001748177","retrieved_at":"2026-08-25T00:17:57+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}